Despite tremendous progress in the last decade, lung adenocarcinoma still represents a
tumor with unfavorable prognosis when detected at advanced clinical stage. High-stage …

Epidermal growth factor receptor (EGFR) is a transmembrane protein with cytoplasmic
kinase activity that transduces important growth factor signaling from the extracellular milieu …

Lung cancers that harbor somatic activating mutations in the gene for the epidermal growth
factor receptor (EGFR) depend on mutant EGFR for their proliferation and survival; therefore …

Epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma are a frequent
class of driver mutations. Single EGFR tyrosine kinase inhibitor (TKI) provides substantial …

Considerable knowledge has accumulated about mutations of the epidermal growth factor
receptor (EGFR)-tyrosine kinase domain since these were first identified in 2004. Patients …

Purpose EGFR-mutant lung cancer was first described as a new clinical entity in 2004. Here,
we present an update on new controversies and conclusions regarding the disease …

Somatic mutations in certain tyrosine kinases have emerged as central 'drivers' of specific
cancers and these mutant proteins are proving to be excellent substrates for targeted …

The discovery of epidermal growth factor receptor (EGFR) mutations in nonsmall cell lung
cancer (NSCLC) has allowed the identification of a subset of patients whose tumours are …

Therapy targeted against the epidermal growth factor receptor (EGFR) has demonstrated
dramatic tumor responses and favorable clinical outcomes in a select group of non-small …

Tyrosine kinase inhibitors directed against the epidermal growth factor receptor (EGFR) are
the first molecular-targeted agents to be approved in the US and other countries for the …